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Abstract
Background The clinical effect of stent treatment has
been evaluated by mainly physicians; only a limited
number of prospective studies have used patient-reported
outcomes for this purpose. The aim of this work was to
study the clinical effect of self-expanding metal stents in
treatment of malignant gastrointestinal obstructions, as
evaluated by patient-reported outcomes, and compare the
rating of the treatment effect by patients and physicians.
Methods Between November 2006 and April 2008, 273
patients treated with SEMS for malignant GI and biliary
obstructions were recruited from nine Norwegian hospitals.
Patients and physicians assessed symptoms independently
at the time of treatment and after 2 weeks using the
European Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 questionnaire supplemented
with specific questions related to obstruction.
Results A total of 162 patients (99 males; median
age = 72 years) completed both assessments and were
included in the study. A significant improvement in the
mean global health score was observed after 2 weeks (from
9 to 18 on a 0–100 scale, P \ 0.03) for all stent locations.
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Both patients and physicians reported a significant reduc-
tion in all obstruction-related symptoms ([20 on the 0–100
scale, P \ 0.006) after SEMS treatment. The physicians
reported a larger mean improvement in symptoms than did
the patients, mainly because they reported more severe
symptoms before treatment.
Conclusion SEMS treatment is effective in relieving
symptoms of malignant GI and biliary obstruction, as
reported by patients and physicians. The physicians, how-
ever, reported a larger reduction in obstructive symptoms
than did the patients. A prospective assessment of patient-
reported outcomes is important in evaluating SEMS
treatment.
Keywords Stents  Palliative care  Gastrointestinal
cancer  Biliary tract neoplasm  Outcome assessment 
Quality of life
Palliative treatment with self-expanding metal stents
(SEMS) is regarded as a safe and highly effective proce-
dure for relief of symptoms caused by malignant obstruc-
tions of the gastrointestinal (GI) tract [1–8]. Most studies
concerning treatment with SEMS, whether randomized,
comparative, or merely descriptive, focus on technical
success (e.g., correct deployment of the stent), clinical
success (restored passage), procedure-related complica-
tions, and cost-effectiveness. Typically, the clinical out-
comes of SEMS treatment have been evaluated by the
physician [9]; only a few prospective studies reported
repeated symptom assessments by the patient [10–16].
Since patients’ and physicians’ ratings of treatment effects
do not always correspond well, palliative treatment efforts
such as SEMS for malignant GI obstructions should be
evaluated by individual outcome measures reported by the
patients as well as by the physicians [17–22].
The main objective of this multicenter study was to use
patient-reported outcomes to evaluate the treatment effects
of SEMS on quality of life (QoL) and symptoms related to
malignant GI and biliary obstruction. An additional aim of
the study was to compare patient- and physician-reported
evaluations of the treatment’s effects.
Materials and methods
Nine Norwegian hospitals performing SEMS treatment for
GI obstructions participated in the present study. The
inclusion period was from November 2006 to April 2008.
Patients were eligible for consecutive inclusion according
to the following criteria: (1) symptoms related to malignant
GI obstruction, (2) indication for treatment with all types of
metal stents established, (3) fluency in oral and written
Norwegian, and (4) cognitive capability to complete the
questionnaires. Patients who received their colonic stent as
a ‘‘bridge to surgery’’ (i.e., to relieve the acute obstruction
prior to elective surgery) and underwent bowel resection
within 2 weeks after stent placement were not asked to
complete the questionnaire after 2 weeks and were thus not
included in the analyses. The study was approved by the
Regional Committee for Medical Research Ethics in
Southern Norway and the Data Protection Supervisor at
Oslo University Hospital, Ulleva˚l. All patients received
oral and written information about the study. Written
informed consent was obtained from all participants.
Stent procedure
All stents were deployed endoscopically under fluoroscopic
guidance. Both covered and uncovered stents were used for
esophageal and biliary stent treatment, while uncovered
stents were used in other locations.
Assessment of patient-reported outcomes
The European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire, EORTC QLQ-
C30, version 3.0 [23], was used to assess patient-reported
outcomes, supplemented with selected questions from
other relevant EORTC organ- and disease-specific modules
(http://www.eortc.be/). The EORTC QLQ-C30 is a cancer-
specific 30-item self-reporting questionnaire consisting of
both multi-item scales and single-item measures. These
include five functional scales (i.e., physical, role, cognitive,
emotional, and social), three symptom scales (i.e., fatigue,
nausea/vomiting, and pain), and six single items (i.e.,
dyspnea, insomnia, appetite loss, constipation, diarrhea,
and financial problems), as well as two questions where the
patients assessed their overall health and QoL on a scale
from 1 to 7. Combining these two scores resulted in a
global health score.
EORTC recommends that organ-specific modules be
used in addition to the core questionnaire to capture diag-
nosis- or treatment-specific problems. For the purpose of the
present study, a selection of questions was made from the
relevant organ-specific modules to reduce the respondent’s
burden and to focus on specific problems pertaining to the
different diagnostic or stent groups. Questions to be
answered by the patients receiving esophageal, biliary, and
colonic stents were selected from the stomach module
EORTC QLQ-STO22 [24], the pancreatic module EORTC
QLQ-PAN26 [25], and the colorectal module EORTC
QLQ-CR38 [26], respectively (Table 2). Patients who
received gastroduodenal stents did not answer any
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additional questions as their main obstruction-related
symptoms, nausea and vomiting, were specifically addres-
sed by the core questionnaire.
Higher scores on the symptom scales and single items
from the core questionnaires and the organ-specific mod-
ules indicated more severe symptoms, while higher scores
on the functional scales indicate better functioning. All
items were to be answered on an ordinal scale ranging from
1 (‘‘Not at all’’) to 4 (‘‘Very much’’), except for the two
modified visual analog scales assessing global health and
QoL; they ranged from 1 to 7. The time frame was the past
7 days. Scale and item scores were transformed into a
continuous scale from 0 to 100, as described in the EORTC
Scoring Manual [27]. A mean score difference of 5–10 is
usually regarded as a small but clinically noticeable change
for the patients, a change between 10–20 as moderate, and
[20 as a large clinical change [28, 29].
Administration of questionnaires
All assessments were performed twice, at inclusion (-2
to ?1 day before/after the procedure) and 2 weeks after
treatment. The questionnaire was administered to the
study participants upon admission by the treating physi-
cian or a study nurse. The same questionnaire was given
to the patients when leaving the hospital. The patients
were instructed to complete the second questionnaire
2 weeks after stent treatment and return it by mail. The
2-week time span between assessments was chosen to
reach the maximum effect of the stent treatment and
reduce the impact of disease progression. To reduce the
influence of recall bias, the patients had to complete the
initial questionnaire no later than the day after the pro-
cedure and the second questionnaire no later than 3 weeks
after treatment. The physicians assessed the same organ-
specific symptoms at inclusion and the second assessment
at hospital discharge or 2 weeks after stent treatment if
the patient was still hospitalized. The same physician was
responsible for the before and after assessment of
symptoms.
Statistical analysis
Power calculations were based on a mean change of 10
with a standard deviation (SD) of 15 of global health,
with 90% power and a 5% level of significance, which
yielded a sample size of 26 patients in each of the
treatment groups for the four stent locations. Wilcoxon
signed-rank test with 5% significance level was used
when evaluating changes of symptoms before and after
treatment. Statistical analyses were performed using SPSS
16.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
A total of 273 patients were eligible for inclusion in the
study, varying from 2 to 105 patients at the nine partici-
pating centers. Two hundred thirty-eight (87%) patients
completed the questionnaire prior to the stent procedure,
and 162 (68%) of these completed both questionnaires.
Twenty-seven patients did not return the second form for
unknown reasons (Fig. 1). Ninety-nine males and 63
females with a median age of 72 years were included.
Clinical and demographic characteristics are given in
Table 1. The most frequent diagnoses were cancer of the
colon and pancreas. Of the 18 patients with gastric cancer
who received stents, eight had obstructions located in the
cardia ventriculi and were treated with esophageal stents.
Ten patients had gastric outlet obstruction and were treated
with duodenal stents.
Patient-reported outcomes
Patients reported a clinically and statistically significant
reduction in all obstruction-related symptoms in all four
stent locations, with a mean reduction of at least 20
(P \ 0.02). Furthermore, a clinically and statistically sig-
nificant improvement in global health function (P \ 0.03)
was observed in all treatment groups. Additionally, various
other symptoms improved significantly: nausea/vomiting
(colon and biliary), appetite loss (biliary and gastroduo-
denal), pain (gastroduodenal and colonic), and constipation
(colonic) (Tables 2, 3, 4, and 5). The total numbers of
patients experiencing symptomatic improvement C 20,
improvement \ 20, or worsening are reported in Table 6.
The scorings from patients who completed the pre-
treatment questionnaire before treatment were similar to
those from patients who completed it the day after treat-
ment. Sixty-four patients (40%) completed the first
assessment the day after stent insertion because of emer-
gency stent treatment or pronounced symptoms before
treatment. The rate of missing items was low, 0.9 and 1.0%
in the two assessments, respectively. For the multi-items
scales, missing values were assigned according to a stan-
dard scoring procedure (EORTCs scoring manual, [27]) by
replacing missing items with the scale mean values, pro-
vided that half or more of the scale items were completed.
Comparison of symptoms evaluated by patients
and physicians
When comparing the patients’ and physicians’ scores, a
significant difference in the answers of six of seven
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questions before treatment was found, whereby the physi-
cians indicated symptoms as more pronounced than the
patients (P \ 0.02). However, when comparing the post-
treatment evaluation, the scores tended to be similar (a
statistically significant difference was found for two
questions, see Table 7). When evaluating the clinical effect
as an improvement in obstructive symptoms, the physicians
reported a larger mean reduction in obstructive symptoms
and, thus, a better treatment effect as compared to the
patients.
The median hospital stay was 4 days (range = 0–64).
Therefore, physicians completed their second symptom
assessment\7 days after the first registration in (131/162)
81% of the cases. The patients completed their second
assessment of symptoms after 2 weeks (assessing symp-
toms between days 7 and 14).
Short-term outcome/complications
During the first week, 12 of 162 patients (7%) experienced
complications: three nonfunctional stents, two stent migra-
tions, two bleeding episodes, two episodes of cholangitis,
one tracheal-esophageal fistula, one stent obstruction by
food impaction, and one stent obstruction by tumor over-
growth. There was no procedure-related mortality.
Discussion
This study is one of very few that evaluates the symp-
tomatic effect of palliative GI stenting based on patient-
reported outcomes. Furthermore, to our knowledge it is the
first to compare patients’ and physicians’ assessments of
the symptomatic effect of SEMS treatment. The present
study demonstrates that the majority of patients found
treatment with SEMS effective in relieving obstructive
symptoms in all GI tract locations. Additionally, patients
reported a significant clinical improvement in global health
after 2 weeks for all four stent locations. The physicians
tended to evaluate pretreatment symptoms as more severe
than did the patients. The postprocedure scorings were
more similar.
This study shows that treatment with SEMS is effective
in relieving symptoms related to malignant GI obstruction.
Fig. 1 Flowchart showing the selection of the 162 patients included in this study
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Our conclusion is strengthened by the fact that patients in this
study were treated at small local centers, not large expert
centers. SEMS as palliative principle seems to be effective
independent of location. With regard to the symptomatic
effect on esophageal and gastric outlet obstructions,
our findings are in accordance with previous studies.
Additionally, were we able to find significantly improved
general well-being and better QoL, which most previous
studies had not been able to document [10, 12]. A study of
colon obstruction using patient-reported outcomes ended
early and was therefore not able to make a conclusion [30].
That physicians’ and patients’ perceptions of symptoms
differ is in line with previous studies in palliative medicine
that compared physicians and patients, although underes-
timation of patients’ symptoms by physicians is more
common [17–21]. We do not know the reasons for the
discrepancies in scoring found in our study; but one plau-
sible explanation may reflect the enthusiasm of the physi-
cians performing these procedures and their needs to justify
the indication. The study was not designed to clarify this
question.
Table 1 Clinical and demographic characteristics of 162 patients
treated by self-expanding metal stents for malignant gastrointestinal
obstruction
Age [median (range)] 72 (33–93)
Gender M/F 99/63
Survival [median (range)] (days) 111 (15–535)
Diagnoses
Colon cancer 49 (30%)
Pancreatic cancer 41 (25%)
Gastric cancer 18 (11%)
Esophageal cancer 28 (17%)
Bile duct cancer 9 (6%)
Other malignanciesa 17 (11%)
Other palliative treatment
Chemotherapy (during day 0–14) 18 (11%)
Radiotherapy (during day 0–14) 7 (4%)
Stent locations
Esophageal 41 (25%)
Gastroduodenal 33 (20%)
Biliary 40 (25%)
Colon 48 (30%)
a Breast cancer, n = 1, lymphoma, n = 1; lung cancer, n = 3;
prostate cancer, n = 2; hepatocellular carcinoma, n = 1; gallbladder
cancer, n = 1; thyroid cancer, n = 1; papillary cancer, n = 1; ovar-
ian cancer, n = 3; duodenal cancer, n = 1; malignant melanoma,
n = 2
Table 2 Scores from EORTC C30a and selected obstruction-related questions from EORTC OES 18 given by 41 patients treated with
esophageal stents
Before After Difference P value
Global health functionb 30.0 (18.0) 39.1 (26.1) 9.2 (26.4) 0.03
Symptom scalesa,c
Nausea/vomiting 37.8 (31.0) 33.7 (31.7) 4.1 (39.6) 0.49
Pain 43.5 (29.6) 51.2 (31.5) -7.7 (34.6) 0.20
Single itemsc
Appetite loss 69.1 (38.3) 61.8 (39.1) 7.3 (41.8) 0.31
Organ-specific questions from EORTC OES 18c
Have you had problems eating solid food? 86.8 (26.3) 51.0 (40.1) 36.0 (51.6) \0.001
Have you had problems eating liquidized or soft food? 63.1 (35.3) 30.0 (37.3) 32.4 (52.3) 0.001
Have you had problems drinking liquids? 38.6 (36.8) 16.7 (26.5) 22.0 (41.2) 0.002
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 3 EORTC C30a results from 33 patients treated with gastro-
duodenal stents
Before After Difference P value
Global health
functionb
22.0 (19.3) 38.4 (26.4) 16.4 (24.8) \0.001
Symptom scalesb
Pain 57.6 (28.6) 39.9 (36.3) 17.7 (36.3) 0.014
Nausea/vomiting 63.1 (31.1) 30.3 (27.5) 32.8 (38.7) \0.001
Single itemsb
Appetite lossc 81.8 (25.1) 65.7 (37.7) 16.2 (34.5) 0.013
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no significant change was found in the excluded scores
b Scale from 0 to 100; high scores represent more severe symptoms
c Scale from 0 to 100; high scores represent higher level of overall
functioning
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The physicians completed the second questionnaire
earlier than the patients (earlier than day 7 for 81% of the
patients). The study protocol did not include a scheduled
follow-up after stent treatment. The patients were often
severely ill, with long travelling distance to hospital, and an
extra hospital visit to allow the physician to perform a
symptom assessment was hence not included in the follow-
up. As the hospital stay related to the stent procedure
usually was of short duration, the physicians’ scoring often
had to be performed at discharge from hospital. However,
it is likely that the questionnaire’s 1-week time format
reduced the influence of the discrepancy of when the
physicians and patients did the second assessment.
Although there were significant improvements for the
group in total, there was interindividual variation and some
patients did not experience improvement in their obstruc-
tive symptoms. A review of the medical charts revealed
that absence of symptomatic improvement often could be
explained by dysfunctional stents, migrations, infections,
pain, or intercurrent diseases during the first 2 weeks. This
represented a limited number of patients and separate
subanalyses were not performed. Furthermore, ongoing
treatment with other modalities (e.g., chemotherapy) can
potentially influence symptom scoring negatively. We
found no significant difference in the scorings of the 25
patients who received chemo- and/or radiation therapy
during the assessment period.
Table 4 Scores from EORTC C30a and selected obstruction-related
questions from EORTC PAN26 from 40 patients treated with biliary
stents
Before After Difference P value
Global health
functionb
30.4 (25.9) 48.3 (28.0) 17.9 (34.3) 0.003
Symptom scalesc
Pain 48.3 (36.2) 28.8 (25.0) 19.6 (31.8) 0.001
Nausea/vomiting 35.0 (30.8) 21.3 (23.3) 13.8 (28.7) 0.005
Single itemsc
Appetite loss 61.7 (41.0) 45.8 (41.8) 15.8 (32.0) 0.007
Organ-specific questions from EORTC PAN 26c
Have you been
itching?
46.6 (39.1) 23.3 (32.2) 23.3 (51.3) 0.01
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was
made; no significant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall
functioning
c Scale from 0 to 100; high scores represent more severe
Table 5 Scores from EORTC C30a and selected questions from EORTC CR38 from 46 patients treated with colon stents
Before After Difference P value
Global health functionb 38.0 (24.8) 48.7 (23.7) 10.7 (24.5) 0.009
Symptom scalesa, c
Pain 49.3 (33.9) 28.4 (30.0) 20.9 (39.0) 0.001
Nausea /vomiting 29.4 (34.1) 13.8 (21.5) 15.6 (33.6) 0.003
Single itemsc
Appetite loss 45.4 (40.8) 31.9 (35.4) 13.5 (45.4) 0.04
Constipation 53.9 (43.7) 24.8 (32.2) 29.1 (46.0) \0.001
Diarrhea 37.6 (37.2) 45.4 (33.6) -7.8 (45.7) 0.26
Organ-specific questions from EORTC CR38c
Have you had abdominal pain? 53.6 (38.2) 32.6 (28.5) 21.0 (37.4) \0.001
Have you felt bloated? 67.4 (36.2) 27.5 (30.0) 40.0 (44.8) \0.001
All values are mean (SD)
a A selection of the EORTC QLQ-C30 most relevant scorings was made; no significant change was found in the excluded scores
b Scale from 0 to 100; high scores represent higher level of overall functioning
c Scale from 0 to 100; high scores represent more severe symptoms
Table 6 Patient-reported symptomatic effect of stent treatment
Number of patients with clinical
effect on C1 symptoms
Number of patients with no
effect or worsening of symptoms
Esophageal stent 34 (81%) 8 (19%)
Gastroduodenal stent 16 (48%) 17 (52%)
Biliary stent 20 (50%) 20 (50%)
Colonic stent 33 (69%) 15 (31%)
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Our study did not identify subgroups of patients that
regularly did not benefit from SEMS treatment and,
therefore, should have received alternative palliative
treatment. This might be due to the relatively low number
of patients included.
Seventy-six patients completed only the first question-
naire. However, as shown in Fig. 1, only 27 patients failed
to complete the second questionnaire for unknown reasons.
It is possible that these patients did not experience the
expected effect of the stent treatment and that this lack of
data could represent a selection bias. However, we know
that these 27 patients did not differ in age, pretreatment
global health, or survival from the 162 repliers. Three of
these 27 patients experienced dysfunctional stents and
needed reinterventions during the first 2 weeks, which
might have influenced their opinion of stent function. Three
patients experienced cholangitis and/or pancreatitis
immediately after biliary stenting but had functional stents.
For the remaining 21 of the 27 patients, there was not
sufficient information in their medical records to explain
why they did not return their second questionnaire.
Conclusion
SEMS treatment is effective in relieving symptoms of
malignant GI and biliary obstruction, according to assess-
ment by both patients and physicians. This study demon-
strates a significant difference in how the physicians and
patients evaluate treatment effects and thereby the impor-
tance of taking patient-reported outcomes into account
when evaluating clinical palliative interventions. Future
studies evaluating SEMS treatment should include pro-
spective assessment of patient-reported outcomes to
increase our knowledge about the efficacy of this treatment.
Acknowledgments The following hospitals participated in the
study: Oslo University Hospital, Ulleva˚l, Department of Gastroen-
terology, Oslo, Norway; Stavanger University Hospital, Department
of Surgery, Stavanger, Norway; Østfold Hospital Trust Fredrikstad,
Department of Internal Medicine, Fredrikstad, Norway; Vestre Viken
Hospital Trust Drammen, Department of Surgery, Drammen,
Norway; Innlandet Hospital Trust Gjøvik, Department of Internal
Medicine, Gjøvik, Norway; Oslo University Hospital, Aker, Depart-
ment of Surgery, Oslo, Norway; Innlandet Hospital Trust Lilleham-
mer, Department of Internal Medicine, Lillehammer, Norway;
Nord- Trøndelag Hospital Trust Levanger, Department of Surgery,
Levanger, Norway; Oslo University Hospital, AHUS, Department of
Surgery, Oslo, Norway.
Disclosures Lene Larssen, Asle W. Medhus, Marianne J. Hjerms-
tad, Hartwig Ko¨rner, Tom Glomsaker, Taran Søberg, Dagfinn
Gleditsch, Øistein Hovde, Arild Nesbakken, Jan K. Tholfsen, Knut
Skreden, and Truls Hauge have no conflicts of interest and no
financial ties to disclose.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Dormann A, Meisner S, Verin N, Wenk LA (2004) Self-
expanding metal stents for gastroduodenal malignancies:
Table 7 Comparison of scoring by patients and physicians before and after stent treatment
Symptom score before stent
treatment
Symptom score after stent
treatment
Change in symptom score
Stent location Patient Physician P value
diff.
Patient Physician P value
diff.
Patient diff.
before/after
Physician diff.
before/after
P value
diff.
Esophagus
Have you had problems eating
solid food?
87 93 0.13 51 58 0.44 37 34 0.78
Have you had problems eating
liquidized or soft food?
63 82 0.002 30 33 0.49 33 49 0.22
Have you had problems drinking
liquids?
39 64 0.001 17 14 0.63 25 50 0.001
Stomach/duodenum
Have you vomited? 63 83 0.002 30 19 0.24 32 65 0.007
Biliary tree
Have you been itching? 47 60 0.015 23 26 0.38 24 34 0.24
Colon
Have you had abdominal pain? 54 70 \0.001 33 12 \0.001 21 58 \0.001
Have you felt bloated? 67 78 0.002 28 15 0.03 40 64 0.007
All values are mean. Scale from 0 to 100; high scores represent more severe symptoms
3168 Surg Endosc (2011) 25:3162–3169
123
systematic review of their clinical effectiveness. Endoscopy
36:543–550
2. Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley
M (2004) Pooled analysis of the efficacy and safety of self-
expanding metal stenting in malignant colorectal obstruction. Am
J Gastroenterol 99:2051–2057
3. Moss A, Morris E, Mac MP (2006) Palliative biliary stents for
obstructing pancreatic carcinoma. Cochrane Database Syst Rev
Cochrane Database Syst Rev 2:CD004200
4. Breitenstein S, Rickenbacher A, Berdajs D, Puhan M, Clavien
PA, Demartines N (2007) Systematic evaluation of surgical
strategies for acute malignant left-sided colonic obstruction. Br
J Surg 94:1451–1460
5. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ
(2007) Self-expanding metallic stents for relieving malignant
colorectal obstruction: a systematic review. Ann Surg 246:24–30
6. Jeurnink SM, Steyerberg EW, Hof G, van Eijck CH, Kuipers EJ,
Siersema PD (2007) Gastrojejunostomy versus stent placement in
patients with malignant gastric outlet obstruction: a comparison
in 95 patients. J Surg Oncol 96(5):389–396
7. Homs MY, Siersema PD (2007) Stents in the GI tract. Expert Rev
Med Devices 4:741–752
8. Sreedharan A, Harris K, Crellin A, Forman D, Everett SM (2009)
Interventions for dysphagia in oesophageal cancer. Cochrane
Database Syst Rev 4:CD005048
9. Larssen L, Medhus AW, Hauge T (2009) Treatment of malignant
gastric outlet obstruction with stents: an evaluation of the
reported variables for clinical outcome. BMC Gastroenterol 9:45
10. Homs MY, Essink-Bot ML, Borsboom GJ, Steyerberg EW,
Siersema PD (2004) Quality of life after palliative treatment for
oesophageal carcinoma—a prospective comparison between stent
placement and single dose brachytherapy. Eur J Cancer 40:1862–
1871
11. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Ham-
merlid E, Lundell L, Ruth M (2005) Stent insertion or endolu-
minal brachytherapy as palliation of patients with advanced
cancer of the esophagus and gastroesophageal junction. Results
of a randomized, controlled clinical trial. Dis Esophagus 18:131–
139
12. van Hooft J, Mutignani M, Repici A, Messmann H, Neuhaus H,
Fockens P (2007) First data on the palliative treatment of patients
with malignant gastric outlet obstruction using the WallFlex
enteral stent: a retrospective multicenter study. Endoscopy 39:
434–439
13. Madhusudhan C, Saluja SS, Pal S, Ahuja V, Saran P, Dash NR,
Sahni P, Chattopadhyay TK (2009) Palliative stenting for relief of
dysphagia in patients with inoperable esophageal cancer: impact
on quality of life. Dis Esophagus 22:331–336
14. Saluja SS, Gulati M, Garg PK, Pal H, Pal S, Sahni P, Chatto-
padhyay TK (2008) Endoscopic or percutaneous biliary drainage
for gallbladder cancer: a randomized trial and quality of life
assessment. Clin Gastroenterol Hepatol 6:944–950
15. Schmidt C, Gerdes H, Hawkins W, Zucker E, Zhou Q, Riedel E,
Jaques D, Markowitz A, Coit D, Schattner M (2009) A pro-
spective observational study examining quality of life in patients
with malignant gastric outlet obstruction. Am J Surg 198:92–99
16. Nagula S, Ishill N, Nash C, Markowitz AJ, Schattner MA,
Temple L, Weiser MR, Thaler HT, Zauber A, Gerdes H (2010)
Quality of life and symptom control after stent placement or
surgical palliation of malignant colorectal obstruction. J Am Coll
Surg 210:45–53
17. Wilson KA, Dowling AJ, Abdolell M, Tannock IF (2000) Per-
ception of quality of life by patients, partners and treating phy-
sicians. Qual Life Res 9:1041–1052
18. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004)
How accurate is clinician reporting of chemotherapy adverse
effects? A comparison with patient-reported symptoms from the
Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485–3490
19. Sonn GA, Sadetsky N, Presti JC, Litwin MS (2009) Differing
perceptions of quality of life in patients with prostate cancer and
their doctors. J Urol 182:2296–2302
20. Pearcy R, Waldron D, O’Boyle C, MacDonagh R (2008) Proxy
assessment of quality of life in patients with prostate cancer: how
accurate are partners and urologists? J R Soc Med 101:133–138
21. Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M
(2006) Assessing health-related quality of life in palliative care:
comparing patient and physician assessments. Eur J Cancer
42:1159–1166
22. Easson AM, Lee KF, Brasel K, Krouse RS (2003) Clinical
research for surgeons in palliative care: challenges and opportu-
nities. J Am Coll Surg 196:141–151
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al
(1993) The European Organization for Research and Treatment
of Cancer QLQ-C30: a quality-of-life instrument for use in
international clinical trials in oncology. J Natl Cancer Inst
85:365–376
24. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer
O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E,
D’haese S, Coens C, European Organisation for Research,
Treatment of Cancer Gastrointestinal, Quality of Life Groups
(2004) Clinical and psychometric validation of a questionnaire
module, the EORTC QLQ-STO 22, to assess quality of life in
patients with gastric cancer. Eur J Cancer 40:2260–2268
25. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA,
Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C, Fernandez
CL, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer
MW, Tihanyi T (1999) Development of a disease specific quality
of life (QoL) questionnaire module to supplement the EORTC
Core Cancer QoL Questionnaire, the QLQ-C30 in patients with
pancreatic cancer. EORTC Study Group on Quality of Life. Eur
J Cancer 35:939–941
26. Sprangers MA, te Velde A, Aaronson NK (1999) The construc-
tion and testing of the EORTC colorectal cancer-specific quality
of life questionnaire module (QLQ-CR38). European Organiza-
tion for Research and Treatment of Cancer Study Group on
Quality of Life. Eur J Cancer 35:238–247
27. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D,
Bottomley A, on behalf of the EORTC Quality of Life Group
(2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. Euro-
pean Organisation for Research and Treatment of Cancer,
Brussels
28. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Inter-
preting the significance of changes in health-related quality-of-
life scores. J Clin Oncol 16:139–144
29. Cocks K, King MT, Velikova G, Fayers PM, Brown JM (2008)
Quality, interpretation and presentation of European Organisation
for Research and Treatment of Cancer quality of life question-
naire core 30 data in randomised controlled trials. Eur J Cancer
44:1793–1798
30. van Hooft JE, Bemelman WA, Breumelhof R, Siersema PD,
Kruyt PM, van der Linde K, Veenendaal RA, Verhulst ML,
Marinelli AW, Gerritsen JJ, van Berkel AM, Timmer R, Grubben
MJ, Scholten P, Geraedts AA, Oldenburg B, Sprangers MA,
Bossuyt PM, Fockens P (2007) Colonic stenting as bridge to
surgery versus emergency surgery for management of acute left-
sided malignant colonic obstruction: a multicenter randomized
trial (Stent-in 2 Study). BMC Surg 7:12
Surg Endosc (2011) 25:3162–3169 3169
123
